Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

Clinical trial NCT06532630 · RECRUITING

Trial details

NCT number: NCT06532630
Sponsor: Shanghai First Song Biotechnology Co., LTD
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

B-Cell Malignancy

Start date: 2023-08-24
Primary completion: 2025-09-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.